AbbVie’s Skyrizi shows promise as personalised treatment for psoriasis
The immunosuppressant reduced inflammation in patients with the skin condition after three days
Read More
Tag: Skyrizi
Skyrizi bags positive psoriatic arthritis results
KEEPsAKE-1 and KEEPsAKE-2 studies demonstrated significant improvements in Skyrizi-treated patients
Read More
Skyrizi bags NICE fast-track
Eligible patients in England and Wales will have access to the drug almost two months earlier.
Read More
NICE recommends Skyrizi, Forxiga
The recommendations are for the indication of plaque psoriasis and type I diabetes, respectively.
Read More
European approval for AbbVie’s Skyrizi
The approval is for the treatment of moderate to severe plaque psoriasis.
Read More
Skyrizi gets US approval for psoriasis
The indication is for adults who are candidates for systemic therapy or phototherapy.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
